Cantor Fitzgerald L. P. Invests $3.79 Million in UroGen Pharma Ltd. (NASDAQ:URGN)

Cantor Fitzgerald L. P. bought a new stake in UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 360,000 shares of the company's stock, valued at approximately $3,787,000. UroGen Pharma accounts for about 0.1% of Cantor Fitzgerald L. P.'s portfolio, making the stock its 29th largest holding. Cantor Fitzgerald L. P. owned about 1.54% of UroGen Pharma as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in URGN. Acorn Capital Advisors LLC purchased a new position in shares of UroGen Pharma in the fourth quarter valued at $16,149,000. Nantahala Capital Management LLC acquired a new stake in shares of UroGen Pharma during the fourth quarter valued at about $14,608,000. Silverarc Capital Management LLC increased its position in shares of UroGen Pharma by 24.3% during the fourth quarter. Silverarc Capital Management LLC now owns 1,120,473 shares of the company's stock worth $11,933,000 after acquiring an additional 219,344 shares during the last quarter. Rosalind Advisors Inc. acquired a new position in shares of UroGen Pharma in the fourth quarter worth about $9,266,000. Finally, Geode Capital Management LLC boosted its holdings in UroGen Pharma by 1.4% in the fourth quarter. Geode Capital Management LLC now owns 461,902 shares of the company's stock valued at $4,919,000 after purchasing an additional 6,265 shares during the last quarter. Hedge funds and other institutional investors own 91.29% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on URGN. HC Wainwright reaffirmed a "buy" rating and issued a $55.00 target price on shares of UroGen Pharma in a research report on Monday, April 28th. Guggenheim reiterated a "buy" rating on shares of UroGen Pharma in a research note on Tuesday, April 29th. D. Boral Capital reissued a "buy" rating and set a $25.00 price objective on shares of UroGen Pharma in a report on Monday, April 28th. LADENBURG THALM/SH SH began coverage on shares of UroGen Pharma in a research note on Wednesday, February 19th. They issued a "buy" rating and a $31.00 target price on the stock. Finally, Scotiabank initiated coverage on UroGen Pharma in a research note on Wednesday, April 16th. They issued a "sector outperform" rating and a $23.00 price target for the company. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, UroGen Pharma currently has a consensus rating of "Buy" and an average target price of $32.86.

UroGen Pharma Stock Performance

Shares of NASDAQ:URGN traded up $0.43 during trading on Wednesday, hitting $10.12. 818,153 shares of the company traded hands, compared to its average volume of 538,825. The stock has a market capitalization of $466.74 million, a price-to-earnings ratio of -3.21 and a beta of 0.66. UroGen Pharma Ltd. has a one year low of $8.94 and a one year high of $20.70. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77. The business's fifty day moving average is $10.60 and its 200-day moving average is $11.02.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last posted its earnings results on Monday, March 10th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.11). The business had revenue of $24.57 million during the quarter, compared to the consensus estimate of $25.25 million. As a group, equities analysts predict that UroGen Pharma Ltd. will post -3.12 earnings per share for the current fiscal year.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.